Kauliv (Teriparatide)

Teriparatide is used as an anabolic therapy for bone loss conditions, targeting the skeletal remodeling pathway.

• Postmenopausal osteoporosis: increases bone mineral density and reduces vertebral and non‑vertebral fracture risk in postmenopausal women.
• Male osteoporosis at high risk of fracture: promotes bone formation to improve skeletal strength in men with severe osteoporosis.
• Glucocorticoid‑induced osteoporosis: counteracts steroid‑related bone loss by stimulating osteoblast activity.

• Teriparatide is a synthetic fragment of human parathyroid hormone that selectively activates the PTH1 receptor on osteoblasts. Receptor activation triggers intracellular signaling cascades, including cAMP production and protein kinase A activation, which enhance osteoblast proliferation, differentiation, and function. The net effect is increased bone matrix synthesis and mineralization, leading to a positive bone balance. This anabolic action contrasts with anti‑resorptive agents that primarily inhibit bone breakdown.

Teriparatide may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea: mild to moderate sensation of stomach upset, usually transient.
• Headache: occasional throbbing or pressure headache that resolves without treatment.
• Dizziness: brief episodes of light‑headedness, particularly after injection.
• Injection site reactions: redness, swelling, itching or mild pain at the subcutaneous site.
• Hypercalcemia: slight increase in blood calcium that is often asymptomatic.

Serious or Rare Side Effects

• Osteosarcoma: extremely rare malignant bone tumor observed in long‑term animal studies, with limited human cases.
• Severe hypercalcemia: marked elevation of calcium that can cause cardiac arrhythmia, renal impairment, or neurological symptoms.
• Hypersensitivity reactions: anaphylactic response or severe skin rash requiring immediate medical attention.
• Hypotension: sudden drop in blood pressure following injection, potentially leading to fainting.
• Acute pancreatitis: rare inflammation of the pancreas presenting with abdominal pain and elevated enzymes.

When prescribing Teriparatide, clinicians should consider several precautionary measures to ensure safe use.

• Assess baseline calcium: verify normal serum calcium and vitamin D levels before initiating therapy.
• Monitor bone turnover: periodic measurement of bone markers and densitometry to evaluate response.
• Evaluate fracture risk: use only in patients with high fracture risk who have failed or cannot tolerate anti‑resorptive agents.
• Limit duration: limit treatment to the approved maximum period (typically 2 years) to reduce rare malignancy risk.
• Contraindications: avoid use in patients with prior radiation therapy involving the skeleton or known bone metastases.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the prefilled syringe.

Teriparatide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Hypercalcemic agents: concurrent use of calcium supplements or vitamin D excess may cause severe hypercalcemia.
• Bisphosphonates: simultaneous administration can blunt the anabolic effect of Teriparatide.

Moderate Interactions (Monitor Closely)

• Corticosteroids: may reduce bone‑building response, requiring close monitoring of bone density.
• Loop diuretics: increase calcium excretion and may alter serum calcium balance.
• Anticonvulsants (e.g., phenytoin): induce hepatic enzymes that could affect calcium metabolism.